268 related articles for article (PubMed ID: 30396593)
21. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
22. 90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.
Cecamore C; Marsili M; Salvatore R; Troiani R; D'Egidio M; Tinari N; Pelliccia P; Chiarelli F; Marcovecchio ML; Breda L
Mod Rheumatol; 2018 Jul; 28(4):637-641. PubMed ID: 29157059
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
24. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
29. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S; Horneff G
Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Sušić G; Lazarević D; Milošević V; Cvetković M; Pavlović D
Clin Rheumatol; 2019 Jan; 38(1):117-124. PubMed ID: 30128913
[TBL] [Abstract][Full Text] [Related]
31. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
32. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
33. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
34. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.
van Straalen JW; de Roock S; Giancane G; Consolaro A; Rygg M; Nordal EB; Rubio-Pérez N; Jelusic M; De Inocencio J; Vojinovic J; Wulffraat NM; Bruijning-Verhagen PCJ; Ruperto N; Swart JF;
Pediatr Rheumatol Online J; 2022 Nov; 20(1):96. PubMed ID: 36376976
[TBL] [Abstract][Full Text] [Related]
35. Correlation of ultrasonography synovitis with disease activity and clinical response to etanercept treatment in juvenile idiopathic arthritis patients.
Zhou L; Gu X
Braz J Med Biol Res; 2019; 52(12):e8565. PubMed ID: 31778437
[TBL] [Abstract][Full Text] [Related]
36. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
Geikowski T; Becker I; Horneff G;
Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
[TBL] [Abstract][Full Text] [Related]
37. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.
Luca NJ; Burnett HF; Ungar WJ; Moretti ME; Beukelman T; Feldman BM; Schwartz G; Bayoumi AM
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1803-1811. PubMed ID: 27059807
[TBL] [Abstract][Full Text] [Related]
39. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
[TBL] [Abstract][Full Text] [Related]
40. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
